nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—Low back pain—Lisinopril—dilated cardiomyopathy	0.0288	0.0387	CcSEcCtD
Duloxetine—Hypersomnia—Lisinopril—dilated cardiomyopathy	0.016	0.0215	CcSEcCtD
Duloxetine—Cardiac fibrillation—Lisinopril—dilated cardiomyopathy	0.016	0.0215	CcSEcCtD
Duloxetine—Gastric irritation—Furosemide—dilated cardiomyopathy	0.0144	0.0193	CcSEcCtD
Duloxetine—Blood cholesterol increased—Furosemide—dilated cardiomyopathy	0.0138	0.0186	CcSEcCtD
Duloxetine—Rash erythematous—Spironolactone—dilated cardiomyopathy	0.0134	0.018	CcSEcCtD
Duloxetine—Diabetic—Lisinopril—dilated cardiomyopathy	0.0125	0.0168	CcSEcCtD
Duloxetine—Epigastric discomfort—Furosemide—dilated cardiomyopathy	0.0106	0.0142	CcSEcCtD
Duloxetine—Blood triglycerides increased—Furosemide—dilated cardiomyopathy	0.00851	0.0114	CcSEcCtD
Duloxetine—Apathy—Furosemide—dilated cardiomyopathy	0.0078	0.0105	CcSEcCtD
Duloxetine—Flat affect—Furosemide—dilated cardiomyopathy	0.00773	0.0104	CcSEcCtD
Duloxetine—Lethargy—Spironolactone—dilated cardiomyopathy	0.00759	0.0102	CcSEcCtD
Duloxetine—Sleep disturbance—Lisinopril—dilated cardiomyopathy	0.00746	0.01	CcSEcCtD
Duloxetine—Inappropriate antidiuretic hormone secretion—Lisinopril—dilated cardiomyopathy	0.0072	0.00966	CcSEcCtD
Duloxetine—Ataxia—Spironolactone—dilated cardiomyopathy	0.00699	0.00939	CcSEcCtD
Duloxetine—Cramp muscle—Spironolactone—dilated cardiomyopathy	0.0067	0.00899	CcSEcCtD
Duloxetine—Gastritis—Spironolactone—dilated cardiomyopathy	0.00658	0.00884	CcSEcCtD
Duloxetine—Disturbance in attention—Furosemide—dilated cardiomyopathy	0.00643	0.00864	CcSEcCtD
Duloxetine—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.00592	0.00795	CcSEcCtD
Duloxetine—Hyperlipidaemia—Lisinopril—dilated cardiomyopathy	0.0058	0.00779	CcSEcCtD
Duloxetine—Laryngitis—Lisinopril—dilated cardiomyopathy	0.0058	0.00779	CcSEcCtD
Duloxetine—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.00568	0.00763	CcSEcCtD
Duloxetine—Renal failure—Spironolactone—dilated cardiomyopathy	0.00563	0.00756	CcSEcCtD
Duloxetine—Endocrine disorder—Lisinopril—dilated cardiomyopathy	0.00505	0.00677	CcSEcCtD
Duloxetine—Urine output increased—Furosemide—dilated cardiomyopathy	0.00504	0.00677	CcSEcCtD
Duloxetine—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.00486	0.00653	CcSEcCtD
Duloxetine—Diabetes mellitus—Furosemide—dilated cardiomyopathy	0.00465	0.00625	CcSEcCtD
Duloxetine—Polyuria—Furosemide—dilated cardiomyopathy	0.00461	0.00619	CcSEcCtD
Duloxetine—Oropharyngeal pain—Lisinopril—dilated cardiomyopathy	0.0046	0.00617	CcSEcCtD
Duloxetine—Alopecia—Spironolactone—dilated cardiomyopathy	0.00455	0.0061	CcSEcCtD
Duloxetine—Oliguria—Lisinopril—dilated cardiomyopathy	0.00454	0.00609	CcSEcCtD
Duloxetine—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00431	0.00578	CcSEcCtD
Duloxetine—Dermatitis exfoliative—Furosemide—dilated cardiomyopathy	0.00429	0.00576	CcSEcCtD
Duloxetine—Thirst—Furosemide—dilated cardiomyopathy	0.00425	0.00571	CcSEcCtD
Duloxetine—Musculoskeletal pain—Lisinopril—dilated cardiomyopathy	0.00423	0.00568	CcSEcCtD
Duloxetine—Neck pain—Lisinopril—dilated cardiomyopathy	0.00423	0.00568	CcSEcCtD
Duloxetine—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00416	0.00558	CcSEcCtD
Duloxetine—Lethargy—Furosemide—dilated cardiomyopathy	0.00413	0.00554	CcSEcCtD
Duloxetine—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.00406	0.00545	CcSEcCtD
Duloxetine—Influenza like illness—Lisinopril—dilated cardiomyopathy	0.00406	0.00545	CcSEcCtD
Duloxetine—Malaise—Spironolactone—dilated cardiomyopathy	0.00404	0.00542	CcSEcCtD
Duloxetine—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00401	0.00538	CcSEcCtD
Duloxetine—Irritability—Furosemide—dilated cardiomyopathy	0.00386	0.00519	CcSEcCtD
Duloxetine—Urinary retention—Furosemide—dilated cardiomyopathy	0.00385	0.00517	CcSEcCtD
Duloxetine—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.00379	0.00509	CcSEcCtD
Duloxetine—Discomfort—Spironolactone—dilated cardiomyopathy	0.00377	0.00506	CcSEcCtD
Duloxetine—Dehydration—Furosemide—dilated cardiomyopathy	0.00376	0.00505	CcSEcCtD
Duloxetine—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.0037	0.00496	CcSEcCtD
Duloxetine—Confusional state—Spironolactone—dilated cardiomyopathy	0.00369	0.00495	CcSEcCtD
Duloxetine—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00366	0.00491	CcSEcCtD
Duloxetine—Cramp muscle—Furosemide—dilated cardiomyopathy	0.00364	0.00489	CcSEcCtD
Duloxetine—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00358	0.00481	CcSEcCtD
Duloxetine—Muscular weakness—Furosemide—dilated cardiomyopathy	0.00357	0.00479	CcSEcCtD
Duloxetine—Sleep disorder—Lisinopril—dilated cardiomyopathy	0.00351	0.00471	CcSEcCtD
Duloxetine—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.00349	0.00469	CcSEcCtD
Duloxetine—Pancreatitis—Furosemide—dilated cardiomyopathy	0.00343	0.0046	CcSEcCtD
Duloxetine—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.00343	0.0046	CcSEcCtD
Duloxetine—Eczema—Lisinopril—dilated cardiomyopathy	0.00338	0.00454	CcSEcCtD
Duloxetine—Hepatic failure—Lisinopril—dilated cardiomyopathy	0.00338	0.00454	CcSEcCtD
Duloxetine—Libido decreased—Lisinopril—dilated cardiomyopathy	0.00327	0.0044	CcSEcCtD
Duloxetine—Somnolence—Spironolactone—dilated cardiomyopathy	0.00325	0.00436	CcSEcCtD
Duloxetine—Pollakiuria—Furosemide—dilated cardiomyopathy	0.00323	0.00434	CcSEcCtD
Duloxetine—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.0032	0.0043	CcSEcCtD
Duloxetine—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.00319	0.00429	CcSEcCtD
Duloxetine—Renal impairment—Lisinopril—dilated cardiomyopathy	0.00319	0.00428	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00316	0.00424	CcSEcCtD
Duloxetine—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.00315	0.00424	CcSEcCtD
Duloxetine—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.00311	0.00418	CcSEcCtD
Duloxetine—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.00309	0.00415	CcSEcCtD
Duloxetine—Renal failure—Furosemide—dilated cardiomyopathy	0.00307	0.00412	CcSEcCtD
Duloxetine—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.00305	0.00409	CcSEcCtD
Duloxetine—Diplopia—Lisinopril—dilated cardiomyopathy	0.00304	0.00408	CcSEcCtD
Duloxetine—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.00304	0.00408	CcSEcCtD
Duloxetine—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.00304	0.00408	CcSEcCtD
Duloxetine—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00301	0.00404	CcSEcCtD
Duloxetine—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.00301	0.00404	CcSEcCtD
Duloxetine—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00295	0.00396	CcSEcCtD
Duloxetine—Face oedema—Lisinopril—dilated cardiomyopathy	0.00293	0.00394	CcSEcCtD
Duloxetine—Urticaria—Spironolactone—dilated cardiomyopathy	0.0029	0.0039	CcSEcCtD
Duloxetine—Irritability—Lisinopril—dilated cardiomyopathy	0.0029	0.00389	CcSEcCtD
Duloxetine—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00289	0.00388	CcSEcCtD
Duloxetine—Ataxia—Lisinopril—dilated cardiomyopathy	0.00285	0.00383	CcSEcCtD
Duloxetine—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.00284	0.00382	CcSEcCtD
Duloxetine—Dehydration—Lisinopril—dilated cardiomyopathy	0.00282	0.00379	CcSEcCtD
Duloxetine—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.00277	0.00372	CcSEcCtD
Duloxetine—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00276	0.00371	CcSEcCtD
Duloxetine—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00274	0.00368	CcSEcCtD
Duloxetine—Breast disorder—Lisinopril—dilated cardiomyopathy	0.00274	0.00368	CcSEcCtD
Duloxetine—Cramp muscle—Lisinopril—dilated cardiomyopathy	0.00273	0.00367	CcSEcCtD
Duloxetine—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.00271	0.00364	CcSEcCtD
Duloxetine—Visual impairment—Furosemide—dilated cardiomyopathy	0.0027	0.00362	CcSEcCtD
Duloxetine—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00269	0.00362	CcSEcCtD
Duloxetine—Gastritis—Lisinopril—dilated cardiomyopathy	0.00269	0.00361	CcSEcCtD
Duloxetine—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.00265	0.00355	CcSEcCtD
Duloxetine—Influenza—Lisinopril—dilated cardiomyopathy	0.00262	0.00352	CcSEcCtD
Duloxetine—Eye disorder—Furosemide—dilated cardiomyopathy	0.00262	0.00351	CcSEcCtD
Duloxetine—Tinnitus—Furosemide—dilated cardiomyopathy	0.00261	0.0035	CcSEcCtD
Duloxetine—Pruritus—Spironolactone—dilated cardiomyopathy	0.00259	0.00347	CcSEcCtD
Duloxetine—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.00257	0.00345	CcSEcCtD
Duloxetine—Sweating increased—Lisinopril—dilated cardiomyopathy	0.00256	0.00343	CcSEcCtD
Duloxetine—Angiopathy—Furosemide—dilated cardiomyopathy	0.00254	0.00341	CcSEcCtD
Duloxetine—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00253	0.00339	CcSEcCtD
Duloxetine—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.0025	0.00336	CcSEcCtD
Duloxetine—Arrhythmia—Furosemide—dilated cardiomyopathy	0.0025	0.00336	CcSEcCtD
Duloxetine—Dysuria—Lisinopril—dilated cardiomyopathy	0.00245	0.00329	CcSEcCtD
Duloxetine—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00244	0.00327	CcSEcCtD
Duloxetine—Malnutrition—Furosemide—dilated cardiomyopathy	0.00244	0.00327	CcSEcCtD
Duloxetine—Erythema—Furosemide—dilated cardiomyopathy	0.00244	0.00327	CcSEcCtD
Duloxetine—Dizziness—Spironolactone—dilated cardiomyopathy	0.00242	0.00325	CcSEcCtD
Duloxetine—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.00242	0.00324	CcSEcCtD
Duloxetine—Flatulence—Furosemide—dilated cardiomyopathy	0.0024	0.00322	CcSEcCtD
Duloxetine—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.0024	0.00322	CcSEcCtD
Duloxetine—Weight increased—Lisinopril—dilated cardiomyopathy	0.00239	0.00321	CcSEcCtD
Duloxetine—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00239	0.0032	CcSEcCtD
Duloxetine—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00237	0.00319	CcSEcCtD
Duloxetine—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.00237	0.00318	CcSEcCtD
Duloxetine—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00234	0.00315	CcSEcCtD
Duloxetine—Vomiting—Spironolactone—dilated cardiomyopathy	0.00232	0.00312	CcSEcCtD
Duloxetine—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.00232	0.00311	CcSEcCtD
Duloxetine—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.00231	0.0031	CcSEcCtD
Duloxetine—Rash—Spironolactone—dilated cardiomyopathy	0.0023	0.00309	CcSEcCtD
Duloxetine—Dermatitis—Spironolactone—dilated cardiomyopathy	0.0023	0.00309	CcSEcCtD
Duloxetine—Renal failure—Lisinopril—dilated cardiomyopathy	0.0023	0.00309	CcSEcCtD
Duloxetine—Vision blurred—Furosemide—dilated cardiomyopathy	0.0023	0.00308	CcSEcCtD
Duloxetine—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.00229	0.00308	CcSEcCtD
Duloxetine—Headache—Spironolactone—dilated cardiomyopathy	0.00229	0.00307	CcSEcCtD
Duloxetine—Jaundice—Lisinopril—dilated cardiomyopathy	0.00228	0.00306	CcSEcCtD
Duloxetine—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00227	0.00305	CcSEcCtD
Duloxetine—Anaemia—Furosemide—dilated cardiomyopathy	0.00225	0.00302	CcSEcCtD
Duloxetine—Agitation—Furosemide—dilated cardiomyopathy	0.00224	0.00301	CcSEcCtD
Duloxetine—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00221	0.00297	CcSEcCtD
Duloxetine—Epistaxis—Lisinopril—dilated cardiomyopathy	0.00221	0.00296	CcSEcCtD
Duloxetine—Vertigo—Furosemide—dilated cardiomyopathy	0.00219	0.00294	CcSEcCtD
Duloxetine—Leukopenia—Furosemide—dilated cardiomyopathy	0.00218	0.00293	CcSEcCtD
Duloxetine—Nausea—Spironolactone—dilated cardiomyopathy	0.00217	0.00292	CcSEcCtD
Duloxetine—Hepatitis—Lisinopril—dilated cardiomyopathy	0.0021	0.00282	CcSEcCtD
Duloxetine—Hallucination—Lisinopril—dilated cardiomyopathy	0.00209	0.00281	CcSEcCtD
Duloxetine—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.00208	0.0028	CcSEcCtD
Duloxetine—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00207	0.00278	CcSEcCtD
Duloxetine—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00207	0.00278	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00206	0.00277	CcSEcCtD
Duloxetine—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00206	0.00276	CcSEcCtD
Duloxetine—Dry mouth—Furosemide—dilated cardiomyopathy	0.00203	0.00272	CcSEcCtD
Duloxetine—Confusional state—Furosemide—dilated cardiomyopathy	0.00201	0.00269	CcSEcCtD
Duloxetine—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00199	0.00267	CcSEcCtD
Duloxetine—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.00199	0.00267	CcSEcCtD
Duloxetine—Tinnitus—Lisinopril—dilated cardiomyopathy	0.00196	0.00263	CcSEcCtD
Duloxetine—Shock—Furosemide—dilated cardiomyopathy	0.00196	0.00263	CcSEcCtD
Duloxetine—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00195	0.00262	CcSEcCtD
Duloxetine—Flushing—Lisinopril—dilated cardiomyopathy	0.00195	0.00262	CcSEcCtD
Duloxetine—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00195	0.00261	CcSEcCtD
Duloxetine—Skin disorder—Furosemide—dilated cardiomyopathy	0.00193	0.00259	CcSEcCtD
Duloxetine—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00192	0.00258	CcSEcCtD
Duloxetine—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00191	0.00256	CcSEcCtD
Duloxetine—Anorexia—Furosemide—dilated cardiomyopathy	0.0019	0.00255	CcSEcCtD
Duloxetine—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00189	0.00254	CcSEcCtD
Duloxetine—Chills—Lisinopril—dilated cardiomyopathy	0.00188	0.00253	CcSEcCtD
Duloxetine—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.00188	0.00252	CcSEcCtD
Duloxetine—Alopecia—Lisinopril—dilated cardiomyopathy	0.00186	0.00249	CcSEcCtD
Duloxetine—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00184	0.00247	CcSEcCtD
Duloxetine—Erythema—Lisinopril—dilated cardiomyopathy	0.00183	0.00245	CcSEcCtD
Duloxetine—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00183	0.00245	CcSEcCtD
Duloxetine—Flatulence—Lisinopril—dilated cardiomyopathy	0.0018	0.00242	CcSEcCtD
Duloxetine—Tension—Lisinopril—dilated cardiomyopathy	0.00179	0.00241	CcSEcCtD
Duloxetine—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.00179	0.0024	CcSEcCtD
Duloxetine—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00179	0.0024	CcSEcCtD
Duloxetine—Nervousness—Lisinopril—dilated cardiomyopathy	0.00178	0.00238	CcSEcCtD
Duloxetine—Back pain—Lisinopril—dilated cardiomyopathy	0.00177	0.00237	CcSEcCtD
Duloxetine—Somnolence—Furosemide—dilated cardiomyopathy	0.00177	0.00237	CcSEcCtD
Duloxetine—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00176	0.00236	CcSEcCtD
Duloxetine—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00173	0.00232	CcSEcCtD
Duloxetine—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00172	0.00231	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00172	0.00231	CcSEcCtD
Duloxetine—Fatigue—Furosemide—dilated cardiomyopathy	0.00171	0.0023	CcSEcCtD
Duloxetine—Tremor—Lisinopril—dilated cardiomyopathy	0.00171	0.0023	CcSEcCtD
Duloxetine—Pain—Furosemide—dilated cardiomyopathy	0.0017	0.00228	CcSEcCtD
Duloxetine—Constipation—Furosemide—dilated cardiomyopathy	0.0017	0.00228	CcSEcCtD
Duloxetine—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.0017	0.00228	CcSEcCtD
Duloxetine—Anaemia—Lisinopril—dilated cardiomyopathy	0.00169	0.00227	CcSEcCtD
Duloxetine—Angioedema—Lisinopril—dilated cardiomyopathy	0.00167	0.00224	CcSEcCtD
Duloxetine—Malaise—Lisinopril—dilated cardiomyopathy	0.00165	0.00221	CcSEcCtD
Duloxetine—Vertigo—Lisinopril—dilated cardiomyopathy	0.00164	0.00221	CcSEcCtD
Duloxetine—Syncope—Lisinopril—dilated cardiomyopathy	0.00164	0.0022	CcSEcCtD
Duloxetine—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00164	0.0022	CcSEcCtD
Duloxetine—Leukopenia—Lisinopril—dilated cardiomyopathy	0.00164	0.0022	CcSEcCtD
Duloxetine—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00163	0.00218	CcSEcCtD
Duloxetine—Propranolol—ADRB1—dilated cardiomyopathy	0.00162	0.543	CrCbGaD
Duloxetine—Palpitations—Lisinopril—dilated cardiomyopathy	0.00162	0.00217	CcSEcCtD
Duloxetine—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00161	0.00216	CcSEcCtD
Duloxetine—Cough—Lisinopril—dilated cardiomyopathy	0.0016	0.00214	CcSEcCtD
Duloxetine—Urticaria—Furosemide—dilated cardiomyopathy	0.00158	0.00212	CcSEcCtD
Duloxetine—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00157	0.00211	CcSEcCtD
Duloxetine—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00157	0.00211	CcSEcCtD
Duloxetine—Chest pain—Lisinopril—dilated cardiomyopathy	0.00156	0.00209	CcSEcCtD
Duloxetine—Myalgia—Lisinopril—dilated cardiomyopathy	0.00156	0.00209	CcSEcCtD
Duloxetine—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00156	0.00209	CcSEcCtD
Duloxetine—Anxiety—Lisinopril—dilated cardiomyopathy	0.00155	0.00208	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00155	0.00208	CcSEcCtD
Duloxetine—Discomfort—Lisinopril—dilated cardiomyopathy	0.00154	0.00206	CcSEcCtD
Duloxetine—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00152	0.00204	CcSEcCtD
Duloxetine—Confusional state—Lisinopril—dilated cardiomyopathy	0.0015	0.00202	CcSEcCtD
Duloxetine—Oedema—Lisinopril—dilated cardiomyopathy	0.00149	0.002	CcSEcCtD
Duloxetine—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00149	0.002	CcSEcCtD
Duloxetine—Infection—Lisinopril—dilated cardiomyopathy	0.00148	0.00199	CcSEcCtD
Duloxetine—Shock—Lisinopril—dilated cardiomyopathy	0.00147	0.00197	CcSEcCtD
Duloxetine—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00147	0.00197	CcSEcCtD
Duloxetine—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00146	0.00196	CcSEcCtD
Duloxetine—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00146	0.00196	CcSEcCtD
Duloxetine—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00145	0.00195	CcSEcCtD
Duloxetine—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00144	0.00194	CcSEcCtD
Duloxetine—Asthenia—Furosemide—dilated cardiomyopathy	0.00143	0.00192	CcSEcCtD
Duloxetine—Anorexia—Lisinopril—dilated cardiomyopathy	0.00142	0.00191	CcSEcCtD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00142	0.00564	CbGpPWpGaD
Duloxetine—Pruritus—Furosemide—dilated cardiomyopathy	0.00141	0.00189	CcSEcCtD
Duloxetine—HTR6—G alpha (s) signalling events—ADRB1—dilated cardiomyopathy	0.0014	0.00557	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.00138	0.00548	CbGpPWpGaD
Duloxetine—NPY1R—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.00137	0.00544	CbGpPWpGaD
Duloxetine—Propranolol—ADRB2—dilated cardiomyopathy	0.00137	0.457	CrCbGaD
Duloxetine—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00136	0.00183	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00136	0.00183	CcSEcCtD
Duloxetine—Insomnia—Lisinopril—dilated cardiomyopathy	0.00135	0.00181	CcSEcCtD
Duloxetine—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00134	0.0018	CcSEcCtD
Duloxetine—Somnolence—Lisinopril—dilated cardiomyopathy	0.00133	0.00178	CcSEcCtD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.00132	0.00524	CbGpPWpGaD
Duloxetine—Dizziness—Furosemide—dilated cardiomyopathy	0.00132	0.00177	CcSEcCtD
Duloxetine—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00131	0.00176	CcSEcCtD
Duloxetine—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.0013	0.00174	CcSEcCtD
Duloxetine—SLC6A3—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.00129	0.00513	CbGpPWpGaD
Duloxetine—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00129	0.00173	CcSEcCtD
Duloxetine—Fatigue—Lisinopril—dilated cardiomyopathy	0.00129	0.00173	CcSEcCtD
Duloxetine—Constipation—Lisinopril—dilated cardiomyopathy	0.00128	0.00171	CcSEcCtD
Duloxetine—Pain—Lisinopril—dilated cardiomyopathy	0.00128	0.00171	CcSEcCtD
Duloxetine—Vomiting—Furosemide—dilated cardiomyopathy	0.00126	0.0017	CcSEcCtD
Duloxetine—Rash—Furosemide—dilated cardiomyopathy	0.00125	0.00168	CcSEcCtD
Duloxetine—Dermatitis—Furosemide—dilated cardiomyopathy	0.00125	0.00168	CcSEcCtD
Duloxetine—Headache—Furosemide—dilated cardiomyopathy	0.00125	0.00167	CcSEcCtD
Duloxetine—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00123	0.00165	CcSEcCtD
Duloxetine—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00122	0.00164	CcSEcCtD
Duloxetine—SLC6A4—Monoamine Transport—TNF—dilated cardiomyopathy	0.0012	0.00476	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Other—CXCR3—dilated cardiomyopathy	0.00119	0.00471	CbGpPWpGaD
Duloxetine—Urticaria—Lisinopril—dilated cardiomyopathy	0.00119	0.00159	CcSEcCtD
Duloxetine—Nausea—Furosemide—dilated cardiomyopathy	0.00118	0.00159	CcSEcCtD
Duloxetine—NPY1R—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.00118	0.00468	CbGpPWpGaD
Duloxetine—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00118	0.00158	CcSEcCtD
Duloxetine—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00118	0.00158	CcSEcCtD
Duloxetine—HTR6—G alpha (s) signalling events—ADRB2—dilated cardiomyopathy	0.00114	0.00451	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—ABCC9—dilated cardiomyopathy	0.00114	0.0045	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.00112	0.00444	CbGpPWpGaD
Duloxetine—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.0011	0.00148	CcSEcCtD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.00109	0.00432	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—ACTN2—dilated cardiomyopathy	0.00109	0.00432	CbGpPWpGaD
Duloxetine—Asthenia—Lisinopril—dilated cardiomyopathy	0.00107	0.00144	CcSEcCtD
Duloxetine—Pruritus—Lisinopril—dilated cardiomyopathy	0.00106	0.00142	CcSEcCtD
Duloxetine—SLC6A2—Monoamine Transport—TNF—dilated cardiomyopathy	0.00103	0.00409	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—GJA1—dilated cardiomyopathy	0.00102	0.00406	CbGpPWpGaD
Duloxetine—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00102	0.00137	CcSEcCtD
Duloxetine—Dizziness—Lisinopril—dilated cardiomyopathy	0.000987	0.00132	CcSEcCtD
Duloxetine—Vomiting—Lisinopril—dilated cardiomyopathy	0.000949	0.00127	CcSEcCtD
Duloxetine—Rash—Lisinopril—dilated cardiomyopathy	0.000941	0.00126	CcSEcCtD
Duloxetine—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00094	0.00126	CcSEcCtD
Duloxetine—Headache—Lisinopril—dilated cardiomyopathy	0.000935	0.00126	CcSEcCtD
Duloxetine—HTR2A—GPCRs, Other—ADRB2—dilated cardiomyopathy	0.000932	0.0037	CbGpPWpGaD
Duloxetine—SLC6A3—Monoamine Transport—TNF—dilated cardiomyopathy	0.000915	0.00363	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—IL10—dilated cardiomyopathy	0.000889	0.00352	CbGpPWpGaD
Duloxetine—Nausea—Lisinopril—dilated cardiomyopathy	0.000886	0.00119	CcSEcCtD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000868	0.00344	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000867	0.00344	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000867	0.00344	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000831	0.00329	CbGpPWpGaD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000807	0.0032	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000806	0.0032	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000788	0.00312	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000788	0.00312	CbGpPWpGaD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000781	0.0031	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000781	0.0031	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000762	0.00302	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000744	0.00295	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000744	0.00295	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000742	0.00294	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000742	0.00294	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000732	0.0029	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000709	0.00281	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000691	0.00274	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000689	0.00273	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000675	0.00268	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000669	0.00265	CbGpPWpGaD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000667	0.00265	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000667	0.00264	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—CD36—dilated cardiomyopathy	0.000665	0.00264	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000657	0.0026	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000657	0.0026	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—FAS—dilated cardiomyopathy	0.00065	0.00258	CbGpPWpGaD
Duloxetine—CYP1A2—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000639	0.00253	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000639	0.00253	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—AGTR1—dilated cardiomyopathy	0.000636	0.00252	CbGpPWpGaD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000633	0.00251	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000633	0.00251	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—GJA1—dilated cardiomyopathy	0.000617	0.00245	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000611	0.00242	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000606	0.0024	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000594	0.00236	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000575	0.00228	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000575	0.00228	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000572	0.00227	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.000569	0.00225	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000566	0.00225	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000566	0.00225	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000555	0.0022	CbGpPWpGaD
Duloxetine—HTR2A—G alpha (q) signalling events—AGTR1—dilated cardiomyopathy	0.000552	0.00219	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000548	0.00217	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000548	0.00217	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000542	0.00215	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—IL10—dilated cardiomyopathy	0.000535	0.00212	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000526	0.00209	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000524	0.00208	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000516	0.00205	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.00051	0.00202	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000509	0.00202	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.0005	0.00198	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.000494	0.00196	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000493	0.00195	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000491	0.00195	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000491	0.00195	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000475	0.00189	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000475	0.00189	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000469	0.00186	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000466	0.00185	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000465	0.00185	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000465	0.00185	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.000447	0.00177	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000446	0.00177	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000442	0.00175	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000435	0.00173	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000433	0.00172	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000428	0.0017	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000427	0.00169	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000426	0.00169	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000421	0.00167	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000419	0.00166	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000417	0.00165	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000417	0.00165	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	0.000416	0.00165	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000413	0.00164	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000405	0.00161	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000402	0.0016	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.0004	0.00159	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000399	0.00158	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000396	0.00157	CbGpPWpGaD
Duloxetine—HTR2A—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.000388	0.00154	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000388	0.00154	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000375	0.00149	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000372	0.00147	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000366	0.00145	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000362	0.00144	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000362	0.00144	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000358	0.00142	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.000347	0.00138	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000347	0.00138	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000339	0.00135	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	0.000338	0.00134	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000337	0.00133	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000326	0.00129	CbGpPWpGaD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000323	0.00128	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000321	0.00127	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.00032	0.00127	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.00032	0.00127	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000306	0.00121	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000304	0.00121	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000297	0.00118	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000296	0.00117	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000296	0.00117	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000292	0.00116	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000291	0.00115	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000291	0.00115	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000288	0.00114	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	0.000285	0.00113	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	0.000285	0.00113	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000278	0.0011	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000278	0.0011	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	0.000272	0.00108	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	0.000272	0.00108	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.00027	0.00107	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000264	0.00105	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000264	0.00104	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000262	0.00104	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000257	0.00102	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—AGT—dilated cardiomyopathy	0.000252	0.000998	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—RAF1—dilated cardiomyopathy	0.000248	0.000982	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000246	0.000976	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000241	0.000956	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000236	0.000934	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000236	0.000934	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000233	0.000926	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000226	0.000895	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000223	0.000886	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000219	0.000869	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000214	0.000848	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000214	0.000848	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000212	0.000841	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000212	0.00084	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ANKRD1—dilated cardiomyopathy	0.000208	0.000824	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000205	0.000811	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000205	0.000811	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	0.000204	0.000807	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—EGFR—dilated cardiomyopathy	0.000203	0.000804	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000199	0.000789	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000196	0.000777	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TAZ—dilated cardiomyopathy	0.000195	0.000775	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000193	0.000767	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000193	0.000764	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.00019	0.000755	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.00019	0.000754	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000186	0.000737	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000186	0.000737	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000184	0.00073	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000181	0.000719	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000181	0.000718	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	0.000177	0.000701	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ANKRD1—dilated cardiomyopathy	0.000176	0.000698	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—RAF1—dilated cardiomyopathy	0.000175	0.000693	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000173	0.000687	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000173	0.000685	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000172	0.000682	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000172	0.000681	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000172	0.000681	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000167	0.000663	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TAZ—dilated cardiomyopathy	0.000166	0.000657	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.000165	0.000656	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000165	0.000652	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000165	0.000652	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.00016	0.000633	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000157	0.000624	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000157	0.000623	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000156	0.000619	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000155	0.000613	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.00015	0.000596	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SDHA—dilated cardiomyopathy	0.00015	0.000594	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000149	0.000592	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000143	0.000567	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000142	0.000564	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000136	0.000537	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000133	0.000529	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000133	0.000528	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000132	0.000523	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000128	0.000506	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000126	0.000501	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000126	0.000501	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000125	0.000497	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000124	0.00049	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000121	0.000481	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—EGFR—dilated cardiomyopathy	0.00012	0.000475	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000118	0.000466	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000116	0.000459	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000116	0.000459	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000114	0.000451	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000111	0.000439	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.00011	0.000435	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.00011	0.000435	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000109	0.000433	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000108	0.000427	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000105	0.000417	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000102	0.000405	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000101	0.000399	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ADRB1—dilated cardiomyopathy	9.88e-05	0.000392	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RAC1—dilated cardiomyopathy	9.72e-05	0.000385	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AGTR1—dilated cardiomyopathy	9.72e-05	0.000385	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AGT—dilated cardiomyopathy	9.29e-05	0.000368	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ADRB2—dilated cardiomyopathy	9.22e-05	0.000366	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	9.14e-05	0.000362	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	8.9e-05	0.000353	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AGTR1—dilated cardiomyopathy	8.44e-05	0.000335	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—RAF1—dilated cardiomyopathy	8.04e-05	0.000319	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	8.01e-05	0.000318	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ADRB2—dilated cardiomyopathy	8.01e-05	0.000318	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	7.92e-05	0.000314	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—EGFR—dilated cardiomyopathy	7.48e-05	0.000297	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RAC1—dilated cardiomyopathy	7.16e-05	0.000284	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—RAF1—dilated cardiomyopathy	6.98e-05	0.000277	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	6.88e-05	0.000273	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AGT—dilated cardiomyopathy	6.84e-05	0.000271	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RAF1—dilated cardiomyopathy	6.45e-05	0.000256	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RAC1—dilated cardiomyopathy	6.22e-05	0.000246	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AGT—dilated cardiomyopathy	5.94e-05	0.000236	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—EGFR—dilated cardiomyopathy	5.51e-05	0.000218	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	4.8e-05	0.00019	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—EGFR—dilated cardiomyopathy	4.79e-05	0.00019	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RAF1—dilated cardiomyopathy	4.75e-05	0.000188	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	4.68e-05	0.000185	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EGFR—dilated cardiomyopathy	4.42e-05	0.000175	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	4.21e-05	0.000167	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RAF1—dilated cardiomyopathy	4.12e-05	0.000163	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GPX1—dilated cardiomyopathy	4.07e-05	0.000161	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CD36—dilated cardiomyopathy	3.96e-05	0.000157	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AGT—dilated cardiomyopathy	3.57e-05	0.000141	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EGFR—dilated cardiomyopathy	3.26e-05	0.000129	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EGFR—dilated cardiomyopathy	2.83e-05	0.000112	CbGpPWpGaD
